Quarterly UpdatesApr 30, 2026, 06:23 AM
ATHE: FDA Aligns on ATH434 Phase 3; A$44.53M Cash
AI Summary
Alterity Therapeutics provided a Q3 FY26 corporate update, highlighting significant progress for its ATH434 program in Multiple System Atrophy (MSA). The company achieved alignment with the FDA on key elements for its planned Phase 3 program and is on track for an End-of-Phase 2 FDA meeting mid-year 2026. New analyses of Phase 2 data demonstrated consistent evidence of ATH434 slowing disease progression in MSA. Additionally, Alterity strengthened its leadership team and reported a strong cash balance of A$44.53 million, providing an estimated 9.4 quarters of funding.
Key Highlights
- Aligned with FDA on key elements for ATH434 Phase 3 program in MSA
- On track for End-of-Phase 2 FDA meeting mid-year 2026 for ATH434
- Phase 2 data showed ATH434 slowed disease progression in MSA using MuSyCA endpoint
- Appointed Dr. Daniel Claassen as Chief Medical Advisor and Ms. Ann Cunningham to Board
- Engaging in discussions with pharmaceutical companies for ATH434 collaboration
- Cash balance of A$44.53M at March 31, 2026
- Operating cash outflows for the quarter were A$4.73M
- Estimated 9.4 quarters of funding available based on current burn rate